Indoramin is a competitive a1 antagonist that also antagonizes agonist effects at H1 and 5-HT receptors. Via a1 antagonism, indoramin lowers blood pressure with minimal tachycardia and decreases the incidence of attacks of Raynaud's phenomenon. Indoramin has modest bioavailability (<30%, with considerable variability), with extensive first-pass metabolism and an elimination t122 ~5 hours; some metabolites may be biologically active. Adverse effects include sedation, dry mouth, and failure of ejaculation. Indoramin is an effective antihypertensive, but has complex pharmacokinetics and lacks a well-defined therapeutic niche. Indoramin is not available in the U.S.
Was this article helpful?
Do You Suffer From High Blood Pressure? Do You Feel Like This Silent Killer Might Be Stalking You? Have you been diagnosed or pre-hypertension and hypertension? Then JOIN THE CROWD Nearly 1 in 3 adults in the United States suffer from High Blood Pressure and only 1 in 3 adults are actually aware that they have it.